2.2. Pharmacokinetics
The pharmacokinetics of semisynthetic derivatives of PPT depends on the hydrophobicity of the molecule. PPT has reportedly been given to the patient as a 30 minutes infusion in skin cancer treatment or via direct application of the cream/solution to the lesion (Ardalani et al., 2017; Lacey et al., 2003). The maximum tolerated dose (MTD) is 120 mg/m2 in human beings, and elimination half-life is up to 5 hours depending on the derivative (Frazier and Price, 2010; Smyth et al., 1985). Clinical studies showed that dermal absorption of this drug is limited, and its metabolism takes place in the liver and kidneys.